Home/Filings/4/0001209191-19-023517
4//SEC Filing

Huyett William 4

Accession 0001209191-19-023517

CIK 0001755237other

Filed

Apr 2, 8:00 PM ET

Accepted

Apr 3, 7:39 PM ET

Size

15.9 KB

Accession

0001209191-19-023517

Insider Transaction Report

Form 4
Period: 2019-04-01
Huyett William
DirectorPRESIDENT
Transactions
  • Award

    Common Stock

    2019-04-01+38,32738,327 total
  • Award

    Employee Stock Option (Right to Buy)

    2019-04-01+221,349221,349 total
    Exercise: $16.81Exp: 2028-01-02Common Stock (221,349 underlying)
  • Award

    Employee Stock Option (Right to Buy)

    2019-04-01+222,002222,002 total
    Exercise: $14.20Exp: 2029-01-29Common Stock (222,002 underlying)
  • Award

    Common Stock

    2019-04-01+39,17978,912 total
Footnotes (6)
  • [F1]In connection with the separation (the "Separation") of Cyclerion Therapeutics, Inc. ("Cyclerion") from Ironwood Pharmaceuticals Inc. ("Ironwood"), the reporting person received a grant of 38,327 restricted stock units, each representing the right to receive a share of Cyclerion common stock, as a result of the adjustment of existing Ironwood restricted stock units held by the reporting person prior to the Separation. The restricted stock unit award, granted as an annual performance award, vests as to 25% of the shares of common stock on the approximate anniversary of the grant.
  • [F2]In connection with the Separation, the reporting person received a grant of 39,179 restricted stock units, each representing the right to receive a share of Cyclerion common stock, as a result of the adjustment of existing Ironwood restricted stock units held by the reporting person prior to the Separation. The restricted stock unit award, granted as an annual performance award, vests as to 25% of the shares of common stock on the approximate anniversary of the grant.
  • [F3]Includes 1,406 shares of Cyclerion common stock received in a pro rata distribution by Ironwood as a result of the Separation.
  • [F4]Represents options to purchase shares of Cyclerion common stock granted to the reporting person in connection with the Separation.
  • [F5]The option, granted as a new hire award, vested as to 25% of the shares of common stock on December 15, 2019, and 2.08333% of the shares of common stock vest each month thereafter for the next 36 months.
  • [F6]The option, granted as an annual performance award, vests as to 2.08333% of the shares of common stock on each monthly anniversary of January 1, 2019.

Issuer

Cyclerion Therapeutics, Inc.

CIK 0001755237

Entity typeother

Related Parties

1
  • filerCIK 0001723846

Filing Metadata

Form type
4
Filed
Apr 2, 8:00 PM ET
Accepted
Apr 3, 7:39 PM ET
Size
15.9 KB